Christopher Missling - Jun 28, 2023 Form 4 Insider Report for ANAVEX LIFE SCIENCES CORP. (AVXL)

Role: President and CEO, Director
Signature: /s/Christopher Missling
Stock symbol: AVXL
Transactions as of: Jun 28, 2023
Transactions value $: -$1,339,310
Form type: 4
Date filed: 6/30/2023, 08:00 PM
Previous filing: Aug 4, 2021
Next filing: Jan 12, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AVXL	Common Stock	Options Exercise	$429K	+268K	+26.32%	$1.60^*	1.29M	Jun 28, 2023	Direct
transaction	AVXL	Common Stock	Sale	-$2.14M	-268K	-20.84%	$7.98	1.02M	Jun 28, 2023	Direct	F1
transaction	AVXL	Common Stock	Options Exercise	$371K	+232K	+22.79%	$1.60^*	1.25M	Jun 29, 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AVXL	Stock Option (Right to Buy)	Options Exercise	$0	-268K	-53.6%	$0.00	232K	Jun 28, 2023	Common Stock	268K	$1.60	Direct
transaction	AVXL	Stock Option (Right to Buy)	Options Exercise	$0	-232K	-100%	$0.00^*	0	Jun 29, 2023	Common Stock	232K	$1.60	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.95 to $8.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.95 to $8.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.